In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.
The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.
In the final part of our interview with Candrice Heath, M.D., she discusses some of the treatment challenges associated with treating pediatric patients with skin of color and how to overcome these obstacles.
In part two of our interview with Candrice Heath, M.D., she explains the most commonly encountered skin conditions when treating young skin of color patients.
Candrice Heath, M.D., shares her tips and tricks for treating young skin of color patients from her presentation at the 2020 Skin of Color Update.
A recent article suggests physicians should be on the lookout for various dermatologic manifestations in pediatric patients suspected of having COVID-19.
In this episode, Candrice Heath, M.D., sits down to discuss her recent presentation at the 2020 Skin of Color Update about clinical pearls for kids, tweens and teens with skin of color. Dr. Heath also explains the most common skin conditions for this patient group, treatment challenges, and much more.
This episode discusses how to become a pediatric dermatologist, including the associated benefits, compensation and responsibilities with Heather Brandling-Bennett, M.D.
The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.
The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6